Rheumatoid arthritis (RA) is a systemic autoimmune disease, primarily affecting joints, but has negative impact on other organs as well. Besides the inherited genetic risk, RA might be developed due to environmental factors or behavior (certain virus infections, smoking, etc.).
The genetic determination is significant, 50% of the risk factors have genetic roots. The treatment efficacy and the therapeutic responsiveness are highly affected by the genetic background.
In order to achieve the desired therapeutic target value after diagnosing the RA, treatment with disease modifying agents should be initiated as early as possible. This is regulated by national and international guidelines.
According to the EULAR recommendations (1) conventional synthetic disease modifying antirheumatic drugs (csDMARDs) are in the first line of the treatment algorithm. In case of treatment failure, when the disease activity remains moderate or high, patients are treated with biological DMARD (bDMARD).
However, among patients treated with biological DMARD, as in the case of a tumor necrosis factor alpha (TNFα) inhibitor infliximab, clinical practice shows that a significant portion of patients fail to respond to the selected drug, thus prediction of therapeutic response before treatment initiation has a crucial importance for both the patients and the clinicians.
The PREDYSTIC® Infliximab RA Kit is an in vitro diagnostic (IVD) test which identifies those bio-naïve patients with RA, who are likely responders or non-responders to infliximab treatment, based on biomarker analysis from peripheral blood sample collected before treatment initiations supporting this decision making.
For the latest information, visit the Linkedin page of the PREDYSTIC® Infliximab RA Kit.
(1) Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020; 79:685–99